HomeCompareNVOS vs ABBV

NVOS vs ABBV: Dividend Comparison 2026

NVOS yields 333333.33% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NVOS wins by $8.099219044190773e+31M in total portfolio value
10 years
NVOS
NVOS
● Live price
333333.33%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.099219044190773e+31M
Annual income
$80,944,421,463,343,720,000,000,000,000,000,000,000.00
Full NVOS calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — NVOS vs ABBV

📍 NVOS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNVOSABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NVOS + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NVOS pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NVOS
Annual income on $10K today (after 15% tax)
$28,333,333.33/yr
After 10yr DRIP, annual income (after tax)
$68,802,758,243,842,160,000,000,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, NVOS beats the other by $68,802,758,243,842,160,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NVOS + ABBV for your $10,000?

NVOS: 50%ABBV: 50%
100% ABBV50/50100% NVOS
Portfolio after 10yr
$4.0496095220953863e+31M
Annual income
$40,472,210,731,671,860,000,000,000,000,000,000,000.00/yr
Blended yield
99.94%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

NVOS
No analyst data
Altman Z
-4.5
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NVOS buys
0
ABBV buys
0
No recent congressional trades found for NVOS or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNVOSABBV
Forward yield333333.33%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$8.099219044190773e+31M$102.3K
Annual income after 10y$80,944,421,463,343,720,000,000,000,000,000,000,000.00$24,771.77
Total dividends collected$8.098906375781879e+31M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NVOS vs ABBV ($10,000, DRIP)

YearNVOS PortfolioNVOS Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$33,344,033$33,333,333.33$11,550$430.00+$33.33MNVOS
2$103,911,171,366$103,875,493,250.26$13,472$627.96+$103911.16MNVOS
3$302,644,656,190,810$302,533,471,237,448.00$15,906$926.08+$302644656.17MNVOS
4$823,817,797,451,856,400$823,493,967,669,732,100.00$19,071$1,382.55+$823817797451.84MNVOS
5$2,095,836,995,961,804,000,000$2,094,955,510,918,530,000,000.00$23,302$2,095.81+$2095836995961804.00MNVOS
6$4,983,251,920,823,462,000,000,000$4,981,009,375,237,783,000,000,000.00$29,150$3,237.93+$4983251920823461888.00MNVOS
7$11,073,835,968,753,321,000,000,000,000$11,068,503,889,198,040,000,000,000,000.00$37,536$5,121.41+$1.1073835968753322e+22MNVOS
8$22,999,277,308,531,336,000,000,000,000,000$22,987,428,304,044,770,000,000,000,000,000.00$50,079$8,338.38+$2.2999277308531335e+25MNVOS
9$44,643,905,199,991,210,000,000,000,000,000,000$44,619,295,973,271,085,000,000,000,000,000,000.00$69,753$14,065.80+$4.464390519999121e+28MNVOS
10$80,992,190,441,907,720,000,000,000,000,000,000,000$80,944,421,463,343,720,000,000,000,000,000,000,000.00$102,337$24,771.77+$8.099219044190773e+31MNVOS

NVOS vs ABBV: Complete Analysis 2026

NVOSStock

Novo Integrated Sciences, Inc., together with its subsidiaries, provides multidisciplinary primary health care related products and services. It operates through two segments, Healthcare Services, and Product Manufacturing and Development. The company offers physiotherapy, chiropractic care, manual/manipulative therapy, occupational therapy, eldercare, massage therapy, acupuncture and functional dry needling, chiropody, stroke and traumatic brain injury/neurological rehabilitation, kinesiology, vestibular therapy, concussion management and baseline testing, trauma sensitive yoga and meditation for concussion-acquired brain injury and occupational stress-PTSD, women's pelvic health program, sports medicine therapy, assistive devices, dietitian, holistic nutrition, fall prevention education, sports team conditioning program, and private personal training services. It also engages in the assessment, diagnosis, treatment, pain management, rehabilitation, education, and prevention of various orthopedic, musculoskeletal, sports injury, and neurological conditions across various demographics, including pediatric, adult, and geriatric populations. In addition, the company offers eldercare physiotherapy services, such as long-term care homes, retirement homes, community based home care physiotherapy, community based group exercise classes and fall prevention programs, and community-based outpatient clinics; and elderly occupational therapy services for retirement home and community, and long-term care sectors. Further, it offers medical technology services, such as telemedicine and remote patient monitoring; and develops and distributes personalized health and wellness product solutions. The company operates 16 owned clinics. The company was incorporated in 2000 and is based in Bellevue, Washington. Novo Integrated Sciences, Inc. operates as a subsidiary of ALMC-ASAP Holdings, Inc.

Full NVOS Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this NVOS vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NVOS vs SCHDNVOS vs JEPINVOS vs ONVOS vs KONVOS vs MAINNVOS vs JNJNVOS vs MRKNVOS vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.